科研动态期刊摘要
用于成人异基因造血细胞移植受者的活体生物治疗产品：一项部分随机、安慰剂对照的1b期试验
Nature Medicine · 2026-11-04
摘要
《自然·医学》，在线发表：2026年11月3日；doi:10.1038/s41591-026-04686-y 在一项1b期研究中，纳入了异基因造血细胞移植受者的开放标签队列和随机对照队列，研究发现，使用研究性、培养的多菌株细菌口服活体生物治疗产品SER-155治疗的安全性与安慰剂相似，并使血流感染减少，表明有必要对该疗法进行进一步临床研究。
English
A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and resulted in fewer bloodstream infections, indicating further clinical investigation of this therapeutic is warranted.